Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine

Antiviral Research

Volumn 144, Issue , 2017, Pages 70-82

  Giarola Silva, Sarah ^a   Coelho dos Reis, Jordana G A ^a   Mourão, Marina Moraes ^a   Campi Azevedo, Ana Carolina ^a   Nakagaki Silva, Erick E ^a   Luiza Silva, Maria ^b   Martins, Marina Angela ^a   Silveira Cassette, Amanda Cardoso de Oliveira ^a   Batista, Maurício Azevedo ^a   Peruhype Magalhães, Vanessa ^a   do Valle Antonelli, Lis Ribeiro do Valle ^a   Leite Ribeiro, José Geraldo ^c   Elói Santos, Silvana Maria ^a,b   Machado, Alexandre Vieira ^a   Teixeira Carvalho, Andréa ^a   Martins Filho, Olindo Assis ^a   Araújo, Márcio Sobreira Silva ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Ministério da Saúde Núcleo Estadual de Minas Gerais   (Brazil)

Author keywords

AS03 adjuvant; Biomarker signature; H1N1 vaccine; Immune response

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CXCL9 CHEMOKINE; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 8; RANTES; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; ALPHA TOCOPHEROL; ASO3B ADJUVANT; CYTOKINE; IMMUNOLOGICAL ADJUVANT; POLYSORBATE; SQUALENE;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN EXPERIMENT; NATURAL KILLER CELL; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UPREGULATION; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); MALE; MIDDLE AGED; SECRETION (PROCESS); TREATMENT OUTCOME; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALPHA-TOCOPHEROL; CYTOKINES; DRUG COMBINATIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019679345     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2017.05.009     Document Type: Article

References (49)

1. Baggiolini, M., Clark-Lewis, I., Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 27 307:1 (1992), 97–101.
2. Baggiolini, M., Walz, A., Kunkel, S.L., Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84:4 (1989), 1045–1049.
3. Bardenheier, B.H., Duderstadt, S.K., Engler, R.J., McNeil, M.M., Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System. Vaccine 34:37 (2016), 4406–4414.
4. Billiau, A., Matthys, P., Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 20:2 (2009), 97–113.
5. Broadbent, A.J., Subbarao, K., Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr. Opin. Virol. 1:4 (2011), 254–262.
6. Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R.D., Nolan, T., Pfaffl, M.W., Shipley, G.L., Vandesompele, J., Wittwer, C.T., Bustin, S.A., The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55:4 (2009), 611–622.
7. Campi-Azevedo, A.C., Gomes, J.A., Teixeira-Carvalho, A., Silveira-Lemos, D., Vitelli-Avelar, D.M., Sathler-Avelar, R., Peruhype-Magalhães, V., Béla, S.R., Silvestre, K.F., Batista, M.A., Schachnik, N.C., Correa-Oliveira, R., Eloi-Santos, S.M., Martins-Filho, O.A., Etiological treatment of Chagas disease patients with benznidazole lead to a sustained pro-inflammatory profile counterbalanced by modulatory events. Immunobiology 220:5 (2015), 564–574.
8. Cao, B., Li, X.W., Mao, Y., Wang, J., Lu, H.Z., Chen, Y.S., Liang, Z.A., Liang, L., Zhang, S.J., Zhang, B., Gu, L., Lu, L.H., Wang, D.Y., Wang, C., National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N. Engl. J. Med. 361:26 (2009), 2507–2517.
9. Coelho-dos-Reis, J.G., Passos, L., Duarte, M.C., Araujo, M.G., Campi-Azevedo, A.C., Teixeira-Carvalho, A., Peruhype-Magalhães, V., Trindade, B.C., Dos Santos Dias, R., Martins, M.L., Carneiro-Proietti, A.B., Guedes, A.C., Gonçalves, D.U., Martins-Filho, O.A., Immunological profile of HTLV-1-infected patients associated with infectious or autoimmune dermatological disorders. PLoS Negl. Trop. Dis., 7(7), 2013, e2328.
10. Coffman, R.L., Sher, A., Seder, R.A., Vaccine adjuvants: putting innate immunity to work. Immunity 33:4 (2010), 492–503.
11. de Castro, M.C., Rocha-Silva, F., Gomes, L.I., Zauli, D.A., de Moraes Mourao, M., de Castro, M.M., Guimarães, R.E., Teixeira-Carvalho, A., Martins-Filho, O.A., Impact of mitomycin C on the mRNA expression signatures of immunological biomarkers in eosinophilic nasal polyposis. Am. J. Rhinol. Allergy 27:1 (2013), e32–41.
12. de Veer, M.J., Holko, M., Frevel, M., Walker, E., Der, S., Paranjape, J.M., Silverman, R.H., Williams, B.R., Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69:6 (2001), 912–920.
13. Domingues, C.M., de Oliveira, W.K., Uptake of pandemic influenza (H1N1)-2009 vaccines in Brazil, 2010. Vaccine 30:32 (2012), 4744–4751.
14. Fiorentino, D.F., Bond, M.W., Mosmann, T.R., Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:6 (1989), 2081–2095.
15. Frey, S., Poland, G., Percell, S., Podda, A., Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21:27–30 (2003), 4234–4237.
16. Galson, J.D., Trück, J., Kelly, D.F., van der Most, R., Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination. Sci. Rep., 6, 2016, 37229.
17. Geissmann, F., Auffray, C., Palframan, R., Wirrig, C., Ciocca, A., Campisi, L., Narni-Mancinelli, E., Lauvau, G., Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol. Cell Biol. 86:5 (2008), 398–408.
18. Girard, M.P., Tam, J.S., Assossou, O.M., Kieny, M.P., The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 28:31 (2010), 4895–4902.
19. Greenberg, M.E., Lai, M.H., Hartel, G.F., Wichems, C.H., Gittleson, C., Bennet, J., Dawson, G., Hu, W., Leggio, C., Washington, D., Basser, R.L., Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361:25 (2009), 2405–2413.
20. Herrera, M.T., Gonzalez, Y., Juarez, E., Hernandez-Sanchez, F., Carranza, C., Sarabia, C., Guzman-Beltran, S., Manjarrez, M.E., Muñoz-Torrico, M., Garcia-Garcia, L., Sada, E., Torres, M., Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees. BMC Infect. Dis., 13, 2013, 544.
21. Jamieson, D.J., Honein, M.A., Rasmussen, S.A., Williams, J.L., Swerdlow, D.L., Biggerstaff, M.S., Lindstrom, S., Louie, J.K., Christ, C.M., Bohm, S.R., Fonseca, V.P., Ritger, K.A., Kuhles, D.J., Eggers, P., Bruce, H., Davidson, H.A., Lutterloh, E., Harris, M.L., Burke, C., Cocoros, N., Finelli, L., MacFarlane, K.F., Shu, B., Olsen, S.J., Novel influenza a (H1N1) pregnancy working group, H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 374:9688 (2009), 451–458.
22. Lee, C.C., Avalos, A.M., Ploegh, H.L., Accessory molecules for Toll-like receptors and their function. Nat. Rev. Immunol. 12:3 (2012), 168–179.
23. Liang, X.F., Li, L., Liu, D.W., Li, K.L., Wu, W.D., Zhu, B.P., Wang, H.Q., Luo, H.M., Cao, L.S., Zheng, J.S., Yin, D.P., Cao, L., Wu, B.B., Bao, H.H., Xu, D.S., Yang, W.Z., Wang, Y., Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N. Engl. J. Med. 364:7 (2011), 638–647.
24. Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:4 (2001), 402–408.
25. Luiza-Silva, M., Campi-Azevedo, A.C., Batista, M.A., Martins, M.A., Avelar, R.S., da Silveira Lemos, D., Bastos Camacho, L.A., de Menezes Martins, R., de Lourdes de Sousa Maia, M., Guedes Farias, R.H., da Silva Freire, M., Galler, R., Homma, A., Leite Ribeiro, J.G., Campos Lemos, J.A., Auxiliadora-Martins, M., Eloi-Santos, S.M., Teixeira-Carvalho, A., Martins-Filho, O.A., Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J. Infect. Dis. 204:6 (2011), 873–883.
26. Magnusson, S.E., Reimer, J.M., Karlsson, K.H., Lilja, L., Bengtsson, K.L., Stertman, L., Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 31:13 (2013), 1725–1733.
27. Malisan, F., Briere, F., Bridon, J.M., Harindranath, N., Mills, F.C., Max, E.E., Banchereau, J., Martinez-Valdez, H., Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J. Exp. Med. 183:3 (1996), 937–946.
28. Marzocchi-Machado, C.M., Lucisano-Valim, Y.M., Receptores para imunoglobulina G (FcγR). Med. (Ribeirao Preto. Online) 38:1 (2005), 82–95.
29. Moore, K.W., O'Garra, A., de Waal Malefyt, R., Vieira, P., Mosmann, T.R., Interleukin-10. Annu. Rev. Immunol. 11 (1993), 165–190.
30. Morel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., Carlsen, H., Kielland, A., Chomez, P., Garçon, N., Van Mechelen, M., Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:13 (2011), 2461–2473.
31. Nakaya, H.I., Clutterbuck, E., Kazmin, D., Wang, L., Cortese, M., Bosinger, S.E., Patel, N.B., Zak, D.E., Aderem, A., Dong, T., Del Giudice, G., Rappuoli, R., Cerundolo, V., Pollard, A.J., Pulendran, B., Siegrist, C.A., Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc. Natl. Acad. Sci. U. S. A 113:7 (2016), 1853–1858.
32. Neumann, G., Kawaoka, Y., The first influenza pandemic of the new millennium. Influenza Other Respir. Viruses 5:3 (2011), 157–166.
33. Nolan, T., Roy-Ghanta, S., Montellano, M., Weckx, L., Ulloa-Gutierrez, R., Lazcano-Ponce, E., Kerdpanich, A., Safadi, M.A., Cruz-Valdez, A., Litao, S., Lim, F.S., de Los Santos, A.M., Weber, M.A., Tinoco, J.C., Mezerville, M.H., Faingezicht, I., Kosuwon, P., Lopez, P., Borja-Tabora, C., Li, P., Durviaux, S., Fries, L., Dubin, G., Breuer, T., Innis, B.L., Vaughn, D.W., Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J. Infect. Dis. 210:4 (2014), 545–557.
34. Ortqvist, A., Bennet, R., Hamrin, J., Rinder, M.R., Lindblad, H., Ohd, J.N., Öhd, J.N., Eriksson, M., Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children. Vaccine 33:22 (2015), 2558–2561.
35. Plennevaux, E., Sheldon, E., Blatter, M., Reeves-Hoche, M.K., Denis, M., Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 375:9708 (2010), 41–48.
36. Poder, A., Simurka, P., Li, P., Roy-Ghanta, S., Vaughn, D., An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. Vaccine 32:9 (2014), 1121–1129.
37. Poehling, K.A.1., Edwards, K.M., Weinberg, G.A., Szilagyi, P., Staat, M.A., Iwane, M.K., Bridges, C.B., Grijalva, C.G., Zhu, Y., Bernstein, D.I., Herrera, G., Erdman, D., Hall, C.B., Seither, R., Griffin, M.R., The underrecognized burden of influenza in young children. N. Engl. J. Med. 355:1 (2006), 31–40.
38. Prosper, O., Saucedo, O., Thompson, D., Torres-Garcia, G., Wang, X., Castillo-Chavez, C., Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza. Math. Biosci. Eng. 8:1 (2011), 141–170.
39. Ramakrishnan, A., Althoff, K.N., Lopez, J.A., Coles, C.L., Bream, J.H., Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines. Cytokine 60:3 (2012), 661–666.
40. Roman, F., Clement, F., Dewe, W., Walravens, K., Maes, C., Willekens, J., De Boever, F., Hanon, E., Leroux-Roels, G., Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol. 18:5 (2011), 835–843.
41. Rousset, F., Garcia, E., Defrance, T., Peronne, C., Vezzio, N., Hsu, D.H., Kastelein, R., Moore, K.W., Banchereau, J., Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A 89:5 (1992), 1890–1893.
42. Saha, B., Jyothi Prasanna, S., Chandrasekar, B., Nandi, D., Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50:1 (2010), 1–14.
43. Sobolev, O., Binda, E., O'Farrell, S., Lorenc, A., Pradines, J., Huang, Y., Duffner, J., Schulz, R., Cason, J., Zambon, M., Malim, M.H., Peakman, M., Cope, A., Capila, I., Kaundinya, G.V., Hayday, A.C., Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat. Immunol. 17:2 (2016), 204–213 Erratum in: Nat Immunol. 17(4), 469.
44. Tokars, J.I., Lewis, P., DeStefano, F., Wise, M., Viray, M., Morgan, O., Gargiullo, P., Vellozzi, C., The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf. 21:5 (2012), 546–552.
45. van de Winkel, J.G., Anderson, C.L., Biology of human immunoglobulin G Fc receptors. J. Leukoc. Biol. 49:5 (1991), 511–524.
46. Vesikari, T., Karvonen, A., Tilman, S., Borkowski, A., Montomoli, E., Banzhoff, A., Clemens, R., Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics, 126(4), 2010 e762–70.
47. Vesikari, T., Pepin, S., Kusters, I., Hoffenbach, A., Denis, M., Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum. Vaccin Immunother. 8:9 (2012), 1283–1292.
48. Wang, H.B., Weller, P.F., Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J. Leukoc. Biol. 83:4 (2008), 817–821.
49. Zhu, F.C., Wang, H., Fang, H.H., Yang, J.G., Lin, X.J., Liang, X.F., Zhang, X.F., Pan, H.X., Meng, F.Y., Hu, Y.M., Liu, W.D., Li, C.G., Li, W., Zhang, X., Hu, J.M., Peng, W.B., Yang, B.P., Xi, P., Wang, H.Q., Zheng, J.S., A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med. 361:25 (2009), 2414–2423.